Tag: CTX

AMSTERDAM: The Pharmaceutical Accountability Foundation (PAF), a group of legal and medical experts and public health advocates, today welcomes the news that the Spanish competition authority CNMC has fined pharmaceutical company Leadiant €10.25 million for its abuse of its market position to overcharge sufferers of a rare genetic disease. Apart...

The Pharmaceutical Accountability Foundation welcomes the news that the Amsterdam UMC (Amsterdam University Medical Centers) has resumed supplying Dutch patients with the rare disease Cerebrotendinous Xanthomathosis (CTX) with pharmacy compounded chenodeoxycholic acid (CDCA). This action became necessary after Leadiant Biosciences had increased the price of one CDCA capsule from €0,28...